Cas:310480-85-4 n-(2-boc-aminoethyl)-4-bromobenzenesulfonamide manufacturer & supplier

Chemical Name:n-(2-boc-aminoethyl)-4-bromobenzenesulfonamide

CAS.NO:310480-85-4

Synonyms:tert-butyl N-[2-[(4-bromophenyl)sulfonylamino]ethyl]carbamate

Molecular Formula:C₁₃H₁₉BrN₂O₄S

Molecular Weight:379.27000

HS Code:2935009090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.417 g/cm3

Index of Refraction:1.547

PSA:92.88000

Exact Mass:378.02500

LogP:4.11470

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like tert-butyl N-[2-[(4-bromophenyl)sulfonylamino]ethyl]carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-butyl N-[2-[(4-bromophenyl)sulfonylamino]ethyl]carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tert-butyl N-[2-[(4-bromophenyl)sulfonylamino]ethyl]carbamate Use and application,tert-butyl N-[2-[(4-bromophenyl)sulfonylamino]ethyl]carbamate technical grade,usp/ep/jp grade.

Related News: There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space. n-(2-boc-aminoethyl)-4-bromobenzenesulfonamide manufacturer The resort island of Jeju off the south coast of South Korea, a popular destination for Chinese tourists, is temporarily suspending the 30-day no-visa entry that it was granting to Chinese and other foreign tourists. n-(2-boc-aminoethyl)-4-bromobenzenesulfonamide supplier The agency’s first recommendation was straightforward: “Stop using the Innova SARS-CoV-2 Antigen Rapid Qualitative Test. Destroy the tests by placing them in the trash or return the tests to Innova using the FedEx return label that was included with the recall letter that Innova sent to customers.” n-(2-boc-aminoethyl)-4-bromobenzenesulfonamide vendor Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. n-(2-boc-aminoethyl)-4-bromobenzenesulfonamide factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.